Overview: Prader-Willi Mutation TestIntroduction: The Prader-Willi Mutation Test detects methylation defects to diagnose Prader-Willi syndrome, causing obesity or developmental delays. Aligned with 2023 ACMG guidelines, it uses PCR for high specificity, supporting genetic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Prader-Willi syndrome.
Other Names: Prader-Willi Assay, PWS Methylation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Prader-Willi testing began in the 1980s with genetic imprinting research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects methylation defects to diagnose Prader-Willi syndrome, guides treatment, and evaluates patients with obesity or developmental delays.
Test Parameters: 1. Methylation Defect
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of obesity, developmental delays, or genetic symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document obesity, developmental delays, or family history of Prader-Willi syndrome. Include current medications, especially growth hormone therapy.
Consent: Written consent required, detailing the tests purpose, Prader-Willi syndrome implications, and risks of sample collection.
Procedural Considerations: Uses methylation-specific PCR to detect Prader-Willi defects. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for genetic diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive methylation defects confirm Prader-Willi syndrome, guiding growth hormone therapy or dietary management. Negative results may require FISH testing.
Specialist Consultation: Consult a geneticist or pediatrician for result interpretation and treatment planning.
Additional Supporting Tests: FISH, SNP array, or clinical evaluation to confirm Prader-Willi syndrome diagnosis.
Test Limitations: Not all cases have detectable methylation defects; clinical correlation is needed. Sample quality affects sensitivity.
References: ACMG Prader-Willi Guidelines, 2023; American Journal of Medical Genetics, Cassidy SB, 2022.
